Current Drug Targets
Title:Editorial (Thematic Issue: Targeting Defective DNA Damage Response Signaling)
Volume: 17 Issue: 2
Author(s): Loredana Campo and Eun-Kyoung Breuer
Affiliation:
Export Options
About this article
Cite this article as:
Campo Loredana and Breuer Eun-Kyoung, Editorial (Thematic Issue: Targeting Defective DNA Damage Response Signaling), Current Drug Targets 2016; 17 (2) . https://dx.doi.org/10.2174/138945011702160105145550
DOI https://dx.doi.org/10.2174/138945011702160105145550 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endothelial Lipase: A Key Player in HDL Metabolism Modulates Inflammation and Atherosclerotic Risk
Mini-Reviews in Medicinal Chemistry Recent Development in Nano-Sized Dosage Forms of Plant Alkaloid Camptothecin-Derived Drugs
Recent Patents on Anti-Cancer Drug Discovery Bladder Cancer: A Simple Model Becomes Complex
Current Genomics Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models
Current Cancer Drug Targets Oxidation Inhibits Iron-Induced Blood Coagulation
Current Drug Targets Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Voltage-Dependent Potassium Channels Kv1.3 and Kv1.5 in Human Cancer
Current Cancer Drug Targets Therapeutic Potential of Targeting Glypican-3 in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Emodin Enhances the Chemosensitivity of Endometrial Cancer by Inhibiting ROS-Mediated Cisplatin-resistance
Anti-Cancer Agents in Medicinal Chemistry Multi-Component Reactions of Cyclohexan-1,3-dione: Synthesis of Fused Pyran, Pyridine, Thiophene and Pyrazole Derivatives with c-Met, Anti-Proliferative Activities
Anti-Cancer Agents in Medicinal Chemistry Semaphorins at the Interface of Development and Cancer
Current Drug Targets Osteoporosis in Patients with Breast and Prostate Cancer: Effect of Disease and Treatment Modalities
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Bicycloheptylamine-Doxorubicin Conjugate: Synthesis and Anticancer Activities in σ2 Receptor-Expressing Cell Lines
Medicinal Chemistry Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry Glyoxalase 1 and 2 Enzyme Inhibitory Activity of 6-Sulfamoylsaccharin and Sulfocoumarin Derivates
Letters in Drug Design & Discovery Ultrasound Contrast Imaging in Cancer –Technical Aspects and Prospects
Current Molecular Imaging (Discontinued) Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy Osteoprotegerin A Physiological and Pharmacological Inhibitor of Bone Resorption.
Current Pharmaceutical Design